| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790014 | Urologic Oncology: Seminars and Original Investigations | 2018 | 7 Pages |
Abstract
Our present results together with currently published data suggest a role for SDC1 shedding in chemotherapy resistance. Determination of serum SDC1 may contribute to the prediction of docetaxel resistance and therefore may help to facilitate clinical decision-making regarding the type and timing of therapy for patients with CRPC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Tibor Ph.D., Sabina M.D., Orsolya M.D., Ph.D., Dávid M.Sc., Péter M.D., Ph.D., D.Sc., András M.D., Miklós M.D., Ilona M.D., Ph.D., D.Sc., Henning M.D., Boris M.D., D.Sc., Shahrokh F. M.D., Ph.D., D.Sc., Gero M.D., D.Sc.,